Seattle Genetics reveals positive data from tisotumab vedotin trial
Category: #health  By Pankaj Singh  Date: 2020-06-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Seattle Genetics reveals positive data from tisotumab vedotin trial

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing tisotumab vedotin for the treatment of patients with relapsed, progressed on or prior treated recurrent/metastatic cervical cancer.

For the record, Tisotumab vedotin is an investigational ADC (antibody-drug conjugate) directed to tissue factor and is being developed by Seattle Genetics, along with Genmab. Results from the trial showed a 24% confirmed ORR (objective response rate) by independent central review with a median duration of response (DOR) of 8.3 months.

Commenting on the trial, Roger Dansey, M.D., Chief Medical Officer, Seattle Genetics, said that first line chemotherapy currently available for recurrent or metastatic cervical cancer are limited, and indicate an unmet need for new treatment options.

Tisotumab vedotin has revealed clinically significant and durable objective responses with a manageable safety profile, and their firm is looking forward to discussing the potential submission of a Biologics License Application with the FDA to support an accelerated approval, said Dansey.

Estimates claim that, in 2020, over 13,500 women may be diagnosed with cervical cancer in the U.S., with around 4,200 projected deaths. Cervical cancer continues to be one of the leading causes of cancer related deaths in women globally, with over 311,000 fatalities annually.

Thanks to human papillomavirus (HPV) vaccine and routine medical examinations, incidences of cervical cancer have lowered substantially across developed economies. However, women are still diagnosed with cervical cancer, which often resurfaces or becomes metastatic.

Sources claim that additional tisotumab vedotin clinical trials are enrolling patients, including combination use of carboplatin, pembrolizumab, or bevacizumab, with a weekly dosing schedule in patients with locally advanced/metastatic cervical cancer. Apart from this, tisotumab vedotin is also being studied in other tissue factors that express tumor types like ovarian and other solid tumors.

Source Credit: https://www.businesswire.com/news/home/20200629005802/en/Seattle-Genetics-Announces-Positive-Topline-Results-Phase



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...